Datasheet for ABIN7233296

Tazemetostat

1 Image

Go to Product page

Overview

Quantity:	5 mg
Application:	Inhibition (Inh)

Product Details

Purpose:	EZH2 inhibitor
Characteristics:	Potent and selective SAM-competitive inhibitor of the lysine methyltransferase EZH2 (Ki = 2.5nM wild type human PRC2-containing). Displayed strong antiproliferative effects against SMARCB1-deleted malignant rhabdoid tumor (MRT) cell lines in vitro. Antitumor activity was also observed in SMARTCB1 mutant mouse xenografts. Displays potent antitumor activity in various cancer models including non-Hodgkins lymphoma, pediatric glioma, small-cell carcinoma of the ovary, and synovial sarcomas. Tazemetostat has also been shown to control inflammatory genes by modulating IRF1, IRF8, and STAT1 levels suggesting therapeutic potential for the treatment of neuroinflammatory diseases associated with microglial activation.
Purity:	>98 %
Chemical Name:	N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide
Formula:	C34H44N4O4
Solubility:	Soluble in DMSO (up to at least 25 mg/ml)

Target Details

Background:	EPZ-6438,Transcription,Epigenetics,Proliferation,Protein methyltransferase,Cancer stem

Target Details

	cells,Inflammation,Cancer,Posttranslational modification,Neurodegeneration,Chromatin
Molecular Weight:	572.75
CAS-No:	1403254-99-8

Application Details

Restrictions:	For Research Use only

Handling

Format:	Powder
Storage:	-20 °C

Images



Molecule

Image 1. /

